产品
编 号：F757146
分子式：C16H15ClN6O2
分子量：358.78
分子式：C16H15ClN6O2
分子量：358.78
产品类型
规格
价格
是否有货
结构图
CAS No: 2972712-63-1
产品详情
生物活性：
KA2507 hydrochloride is a potent and highly selective inhibitor of HDAC6 (IC50=2.5 nM) with no significant toxicities. KA2507 hydrochloride shows antitumor efficacy and immune modulatory effects.
体内研究：
KA2507 hydrochloride (100-200 mg/kg; p.o.; daily; for 20 days) inhibits tumor growth in the syngeneic B16-F10 mouse melanoma model.KA2507 hydrochloride also demonstrates antitumor efficacy in CT26 and MC38 colorectal cancer models.Analysis of tumor samples also indicates modulation of biomarkers of antitumor immunity at efficacious dosing, with KA2507 hydrochloride administration resulting in reduced STAT3 activation (as measured by phospho-STAT3, an important suppressor of the antitumor immune response), reduced PD-L1 expression, and increased expression of MHC class I.KA2507 hydrochloride exhibits poor oral bioavailability (mice 15%) and Cmax (mice 300 ng/mL) following oral administration (mice 200 mg/kg).Animal Model:Male C57BL/6 mice, B16-F10 melanoma model
Dosage:100 mg/kg, 200 mg/kg,
Administration:P.o.; once a day for 20 days
Result:Inhibited tumor growth in the syngeneic B16-F10 mouse melanoma model.
Animal Model:Male C57BL/6 mice, B16-F10 melanoma model
Dosage:200 mg/kg (Pharmacokinetic Analysis)
Administration:Oral administration
Result:Oral bioavailability (15%), Cmax (300 ng/mL).
体外研究：
KA2507 hydrochloride does not inhibit the in vitro proliferation of mouse or human cancer cells at concentrations that are selective for HDAC6 inhibition. The anti-proliferative effects are only observed at high concentrations of KA2507 hydrochloride, which combines with the increased acetylation of histone H3 suggests that the anti-proliferative effects of KA2507 hydrochloride are attributable to off-target inhibition of class I HDAC as well as HDAC6.
KA2507 hydrochloride is a potent and highly selective inhibitor of HDAC6 (IC50=2.5 nM) with no significant toxicities. KA2507 hydrochloride shows antitumor efficacy and immune modulatory effects.
体内研究：
KA2507 hydrochloride (100-200 mg/kg; p.o.; daily; for 20 days) inhibits tumor growth in the syngeneic B16-F10 mouse melanoma model.KA2507 hydrochloride also demonstrates antitumor efficacy in CT26 and MC38 colorectal cancer models.Analysis of tumor samples also indicates modulation of biomarkers of antitumor immunity at efficacious dosing, with KA2507 hydrochloride administration resulting in reduced STAT3 activation (as measured by phospho-STAT3, an important suppressor of the antitumor immune response), reduced PD-L1 expression, and increased expression of MHC class I.KA2507 hydrochloride exhibits poor oral bioavailability (mice 15%) and Cmax (mice 300 ng/mL) following oral administration (mice 200 mg/kg).Animal Model:Male C57BL/6 mice, B16-F10 melanoma model
Dosage:100 mg/kg, 200 mg/kg,
Administration:P.o.; once a day for 20 days
Result:Inhibited tumor growth in the syngeneic B16-F10 mouse melanoma model.
Animal Model:Male C57BL/6 mice, B16-F10 melanoma model
Dosage:200 mg/kg (Pharmacokinetic Analysis)
Administration:Oral administration
Result:Oral bioavailability (15%), Cmax (300 ng/mL).
体外研究：
KA2507 hydrochloride does not inhibit the in vitro proliferation of mouse or human cancer cells at concentrations that are selective for HDAC6 inhibition. The anti-proliferative effects are only observed at high concentrations of KA2507 hydrochloride, which combines with the increased acetylation of histone H3 suggests that the anti-proliferative effects of KA2507 hydrochloride are attributable to off-target inhibition of class I HDAC as well as HDAC6.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备